1. [CASE 1 — QUESTION 1]
A 71-year-old man presents with newly diagnosed metastatic prostate cancer. Bone scan and MRI reveal diffuse vertebral metastases, including an epidural deposit at L1 that abuts but does not yet compress the spinal cord. He reports new mild lower-extremity weakness and back pain. The oncology team plans to begin androgen deprivation therapy. A resident suggests starting a depot GnRH agonist (leuprolide) as monotherapy today. Which of the following is the most important pharmacologic concern with initiating leuprolide monotherapy in this specific patient?
A) Leuprolide will suppress testosterone too slowly over several months, during which the tumor will progress unchecked because GnRH agonists have no meaningful effect on the gonadal axis
B) Leuprolide will cause an immediate and permanent loss of all pituitary hormone secretion, producing panhypopituitarism that endangers the patient
C) Leuprolide, as a GnRH agonist, transiently activates the GnRH receptor before downregulation occurs, producing an initial surge in LH and testosterone (the flare); in a patient with epidural metastatic disease near the cord, this testosterone flare could acutely stimulate tumor growth and precipitate spinal cord compression
D) Leuprolide will produce an immediate and dangerous fall in testosterone that causes acute tumor lysis syndrome from rapid tumor cell death
E) Leuprolide is ineffective in prostate cancer because the tumor is androgen-independent at the metastatic stage, so another drug class is required
ANSWER: C
Rationale:
This question asked you to identify the principal pharmacologic concern with starting a GnRH agonist as monotherapy in a prostate cancer patient with cord-threatening metastases. GnRH agonists such as leuprolide first activate the GnRH receptor before continuous stimulation causes receptor downregulation; this produces an initial surge of LH and testosterone — the flare — during the first one to two weeks of therapy. In a patient with epidural metastatic disease abutting the spinal cord, this testosterone flare can transiently stimulate androgen-sensitive tumor growth and precipitate or worsen spinal cord compression, a neurologic emergency. This concern is the basis for either using a GnRH antagonist (immediate suppression without flare) or covering the flare with an antiandrogen when an agonist is used.
Option A: Option A is incorrect because GnRH agonists do affect the gonadal axis profoundly; the issue is the initial flare, not a lack of effect, and testosterone does fall to castrate levels within a few weeks.
Option B: Option B is incorrect because leuprolide does not cause permanent panhypopituitarism; it selectively suppresses the gonadal axis through GnRH receptor downregulation, and the effect is reversible on discontinuation.
Option D: Option D is incorrect because the danger is the initial testosterone surge (flare), not an immediate testosterone fall causing tumor lysis; tumor lysis syndrome is not a characteristic complication of GnRH agonist initiation in prostate cancer.
Option E: Option E is incorrect because newly diagnosed metastatic prostate cancer is typically castration-sensitive and responds to androgen deprivation; GnRH agonists are a mainstay of therapy, so the premise of androgen independence is wrong here.
2. [CASE 1 — QUESTION 2]
Continuing with the same patient. The team decides that if a GnRH agonist is to be used, the testosterone flare must be pharmacologically covered. They add an antiandrogen (bicalutamide) starting before and overlapping the leuprolide initiation. Which of the following best describes how the antiandrogen protects this patient during the flare period?
A) Bicalutamide competitively blocks the androgen receptor in prostate tumor cells, so that even though leuprolide transiently raises testosterone during the flare, the surging testosterone cannot stimulate tumor growth because its receptor is blocked at the target tissue
B) Bicalutamide prevents the pituitary from releasing LH in response to leuprolide, thereby eliminating the testosterone surge at its source
C) Bicalutamide accelerates leuprolide-induced GnRH receptor downregulation, shortening the time to castrate testosterone and preventing any flare from occurring
D) Bicalutamide inhibits testicular testosterone synthesis directly, so no testosterone is produced during the flare period
E) Bicalutamide converts leuprolide from an agonist into an antagonist at the GnRH receptor, abolishing the flare pharmacologically
ANSWER: A
Rationale:
This question asked you to explain how an antiandrogen protects a prostate cancer patient during the GnRH agonist flare. Bicalutamide is a competitive androgen receptor antagonist; it binds the androgen receptor in prostate tumor cells and blocks androgen-driven signaling at the target tissue. During the leuprolide flare, testosterone transiently surges, but because the androgen receptor is competitively blocked, the surging testosterone cannot stimulate tumor growth — protecting the patient from flare-related disease progression and cord compression. The antiandrogen is started before and overlapped with the agonist precisely to cover this window.
Option B: Option B is incorrect because bicalutamide does not block pituitary LH release; it acts at the androgen receptor in peripheral target tissues, and the testosterone surge still occurs — it is simply rendered ineffective at the receptor.
Option C: Option C is incorrect because bicalutamide does not accelerate GnRH receptor downregulation or shorten the time to castrate testosterone; it works downstream at the androgen receptor, not at the pituitary GnRH receptor.
Option D: Option D is incorrect because bicalutamide is an androgen receptor antagonist, not an inhibitor of testicular testosterone synthesis; testosterone is still produced (and surges) during the flare, but its action is blocked at the receptor.
Option E: Option E is incorrect because bicalutamide does not convert leuprolide into an antagonist; leuprolide remains an agonist that produces the flare, and bicalutamide simply blocks the downstream androgen effect.
3. [CASE 1 — QUESTION 3]
Continuing with the same patient. The team reconsiders and elects to avoid the flare risk altogether by choosing a GnRH antagonist (degarelix) rather than a GnRH agonist. Which of the following correctly explains why a GnRH antagonist achieves testosterone suppression without producing a flare?
A) A GnRH antagonist first strongly activates the GnRH receptor to deplete pituitary LH stores, after which testosterone falls, but the initial activation is too brief to cause clinically significant flare
B) A GnRH antagonist works at the adrenal cortex to block testosterone synthesis directly, bypassing the pituitary entirely and avoiding any pituitary-mediated flare
C) A GnRH antagonist stimulates dopamine release at the pituitary, which inhibits LH secretion and lowers testosterone gradually without a surge
D) A GnRH antagonist produces a delayed testosterone surge after several weeks, which is less dangerous than the immediate flare of an agonist because the tumor has been treated by then
E) A GnRH antagonist competitively blocks the GnRH receptor from the outset, immediately preventing GnRH-driven LH and FSH secretion; because the receptor is blocked rather than transiently activated, testosterone falls promptly without the initial surge (flare) that characterizes GnRH agonist initiation
ANSWER: E
Rationale:
This question asked you to explain why a GnRH antagonist suppresses testosterone without a flare. GnRH antagonists (degarelix, and the oral agents relugolix and elagolix) competitively block the GnRH receptor from the moment of administration. Because the receptor is blocked rather than transiently activated, there is no initial LH and FSH surge; gonadotropin secretion is suppressed immediately and testosterone falls promptly to castrate levels without the flare that characterizes GnRH agonist initiation. This makes antagonists particularly useful when an immediate, flare-free testosterone drop is needed, as in a patient with cord-threatening metastatic disease.
Option A: Option A is incorrect because a GnRH antagonist does not activate the receptor to deplete LH stores; it blocks the receptor from the outset, so there is no activation phase and no flare.
Option B: Option B is incorrect because GnRH antagonists act at the pituitary GnRH receptor, not at the adrenal cortex; they suppress testosterone by blocking gonadotropin secretion, not by directly inhibiting adrenal synthesis.
Option C: Option C is incorrect because GnRH antagonists do not work by stimulating dopamine release; they competitively block the GnRH receptor, and dopamine is unrelated to their mechanism of gonadotropin suppression.
Option D: Option D is incorrect because GnRH antagonists do not produce a delayed testosterone surge; they suppress testosterone immediately and never cause a flare, which is precisely their advantage over agonists.
4. [CASE 1 — QUESTION 4]
Continuing with the same patient. After stabilization, he is transitioned to oral relugolix for ongoing androgen deprivation. Several months later he is hospitalized for new atrial fibrillation and started on a strong P-glycoprotein (P-gp) inhibitor. Which of the following correctly describes the pharmacokinetic interaction and the expected effect on relugolix exposure?
A) The P-gp inhibitor induces hepatic CYP3A4, accelerating relugolix metabolism and decreasing its plasma exposure, risking loss of testosterone suppression
B) Relugolix is a substrate of intestinal P-glycoprotein; a strong P-gp inhibitor reduces efflux of relugolix back into the gut lumen during absorption, increasing the fraction absorbed and markedly raising relugolix plasma exposure, so co-administration with strong P-gp inhibitors should be avoided when possible or managed with dose-timing separation and monitoring
C) Relugolix is eliminated unchanged by the kidney and is not a substrate of P-gp, so the P-gp inhibitor has no effect on its exposure
D) The P-gp inhibitor displaces relugolix from plasma albumin, increasing renal clearance and lowering total relugolix exposure
E) The P-gp inhibitor converts relugolix into an active metabolite with greater GnRH receptor affinity, enhancing efficacy without any safety concern
ANSWER: B
Rationale:
This question asked you to characterize the relugolix–P-gp inhibitor interaction. Relugolix is a substrate of the intestinal efflux transporter P-glycoprotein (P-gp), which normally pumps a portion of absorbed relugolix back into the gut lumen, limiting its bioavailability. A strong P-gp inhibitor reduces this efflux, allowing more relugolix to be absorbed and markedly increasing its plasma exposure. Because excessive exposure can deepen axis suppression and raise safety concerns, the relugolix labeling advises avoiding co-administration with strong oral P-gp inhibitors when possible; if unavoidable, strategies include separating the timing of administration and close monitoring.
Option A: Option A is incorrect because P-gp inhibitors do not induce CYP3A4, and the net effect is increased (not decreased) relugolix exposure from reduced intestinal efflux.
Option C: Option C is incorrect because relugolix is a P-gp substrate with low oral bioavailability and is not eliminated primarily unchanged by the kidney; the P-gp interaction is clinically significant.
Option D: Option D is incorrect because the dominant mechanism is reduced intestinal P-gp efflux increasing absorption, not albumin displacement increasing renal clearance; the interaction raises, not lowers, exposure.
Option E: Option E is incorrect because relugolix is not converted into a higher-affinity active metabolite by P-gp inhibition; the interaction increases exposure to relugolix itself and carries a genuine safety concern.
5. [CASE 2 — QUESTION 5]
A 46-year-old woman with acromegaly from a GH-secreting pituitary macroadenoma has persistently elevated IGF-1 after transsphenoidal surgery. The endocrinologist plans medical therapy with a somatostatin analog and selects octreotide LAR as first-line. Which of the following best explains the receptor pharmacology that makes octreotide an appropriate first-line choice for most patients with acromegaly?
A) Octreotide is a pan-somatostatin-receptor agonist with equal affinity for all five SSTR subtypes, so it suppresses GH regardless of tumor receptor expression
B) Octreotide is a GH receptor antagonist that blocks peripheral IGF-1 generation without acting on the pituitary tumor at all
C) Octreotide selectively activates SSTR1 and SSTR4, the subtypes most abundant on somatotroph adenomas, accounting for its efficacy
D) Octreotide is a somatostatin analog selective for SSTR2 and SSTR5; because SSTR2 predominates on most GH-secreting pituitary adenomas (somatotrophinomas), octreotide effectively suppresses GH secretion in the majority of patients with acromegaly, making it an appropriate first-line agent
E) Octreotide works by antagonizing GHRH receptors on somatotroph cells, preventing GHRH-driven GH secretion
ANSWER: D
Rationale:
This question asked you to explain the receptor basis for octreotide as first-line therapy in acromegaly. Octreotide is a somatostatin analog selective for SSTR2 and SSTR5. Because SSTR2 is the dominant somatostatin receptor subtype expressed on most GH-secreting pituitary adenomas (somatotrophinomas), octreotide's SSTR2 agonism effectively suppresses GH secretion in the majority of patients with acromegaly, which is why it (and lanreotide, with the same selectivity) is an appropriate first-line medical therapy.
Option A: Option A is incorrect because octreotide is not a pan-receptor agonist with equal affinity for all five subtypes; it is SSTR2/SSTR5-selective, and pasireotide is the pan-receptor agent.
Option B: Option B is incorrect because octreotide is a somatostatin receptor agonist acting on the pituitary tumor, not a GH receptor antagonist; pegvisomant is the GH receptor antagonist that blocks peripheral IGF-1 generation.
Option C: Option C is incorrect because octreotide is selective for SSTR2 and SSTR5, not SSTR1 and SSTR4; SSTR2 (not SSTR1/SSTR4) predominates on somatotroph adenomas.
Option E: Option E is incorrect because octreotide does not antagonize GHRH receptors; it activates inhibitory somatostatin receptors (SSTR2/SSTR5) to suppress GH secretion, a fundamentally different mechanism from GHRH receptor blockade.
6. [CASE 2 — QUESTION 6]
Continuing with the same patient. After several months on maximally dosed octreotide LAR, her IGF-1 remains elevated and symptoms persist. The endocrinologist considers switching to pasireotide. Which of the following best explains the receptor-based rationale for expecting pasireotide to succeed where octreotide failed?
A) Pasireotide is an SSTR2-only agonist with much greater potency than octreotide at the same single receptor, so it overcomes resistance purely through higher SSTR2 affinity
B) Pasireotide is a pan-somatostatin-receptor agonist with high affinity for SSTR1, SSTR2, SSTR3, and SSTR5; in tumors that respond poorly to octreotide because of low SSTR2 expression, pasireotide's broader activity — particularly at SSTR5 — can achieve GH and IGF-1 control that SSTR2-selective agents cannot
C) Pasireotide is a GH receptor antagonist, so it works by a completely different mechanism that does not depend on tumor somatostatin receptor expression
D) Pasireotide stimulates dopamine D2 receptors on the somatotroph adenoma, adding a dopaminergic mechanism absent from octreotide
E) Pasireotide antagonizes SSTR2, relieving a paradoxical SSTR2-mediated escape phenomenon that caused octreotide to fail
ANSWER: B
Rationale:
This question asked you to explain why pasireotide may succeed in acromegaly after octreotide failure. Pasireotide is a pan-somatostatin-receptor agonist with high affinity for SSTR1, SSTR2, SSTR3, and SSTR5. Some GH-secreting adenomas respond poorly to octreotide because they express relatively low levels of SSTR2 (octreotide's principal target). Pasireotide's broader receptor activity — particularly its strong SSTR5 agonism — allows it to suppress GH and IGF-1 in tumors that are SSTR2-poor but SSTR5-expressing, achieving control that SSTR2-selective agents cannot. This broader receptor coverage is the rationale for switching, though at the cost of a higher hyperglycemia rate.
Option A: Option A is incorrect because pasireotide is not an SSTR2-only agonist; its advantage in octreotide-resistant tumors comes from its broader receptor coverage (especially SSTR5), not merely greater SSTR2 potency.
Option C: Option C is incorrect because pasireotide is a somatostatin receptor agonist whose effect depends on tumor receptor expression, not a GH receptor antagonist; pegvisomant is the GH receptor antagonist.
Option D: Option D is incorrect because pasireotide does not stimulate dopamine D2 receptors; it acts at somatostatin receptors, and dopaminergic therapy (cabergoline) is a separate strategy.
Option E: Option E is incorrect because pasireotide is an SSTR2 agonist, not an antagonist; there is no SSTR2-mediated escape phenomenon being relieved by antagonism, and the benefit comes from broader agonism including SSTR5.
7. [CASE 2 — QUESTION 7]
Continuing with the same patient. After switching to pasireotide, her IGF-1 normalizes, but at follow-up her fasting glucose is 192 mg/dL and HbA1c has risen substantially; she was previously normoglycemic and is not obese. Which of the following best explains the mechanism of pasireotide-induced hyperglycemia?
A) Pasireotide's potent agonism at SSTR5 on pancreatic beta cells inhibits adenylyl cyclase (Gi coupling), lowering cAMP and suppressing glucose-stimulated insulin secretion; because this insulin suppression outweighs the concurrent SSTR2-mediated glucagon suppression, the net effect is impaired insulin secretion relative to glucose load, producing hyperglycemia
B) Pasireotide stimulates hepatic gluconeogenesis directly by activating SSTR3 receptors on hepatocytes, independent of any effect on insulin
C) Pasireotide causes hyperglycemia by inducing severe insulin resistance in skeletal muscle through blockade of GLUT4 transporters
D) Pasireotide stimulates glucagon secretion from pancreatic alpha cells via SSTR2 agonism, and the resulting hyperglucagonemia drives the hyperglycemia
E) Pasireotide damages pancreatic beta cells through a direct cytotoxic effect unrelated to somatostatin receptor signaling
ANSWER: A
Rationale:
This question asked you to explain pasireotide-induced hyperglycemia. Pancreatic beta cells express SSTR5, and pasireotide's potent SSTR5 agonism inhibits adenylyl cyclase (Gi coupling), lowering intracellular cAMP and suppressing glucose-stimulated insulin secretion. Although SSTR2 agonism simultaneously suppresses glucagon from alpha cells, the insulin suppression predominates at therapeutic doses, so the net effect is impaired insulin secretion relative to the ambient glucose load — producing hyperglycemia in roughly 73% of pasireotide-treated patients, substantially more than with octreotide or lanreotide.
Option B: Option B is incorrect because pasireotide does not stimulate hepatic gluconeogenesis via hepatocyte SSTR3; the hyperglycemia arises from suppressed pancreatic insulin secretion, not a direct hepatic effect.
Option C: Option C is incorrect because the dominant mechanism is impaired insulin secretion (a beta-cell secretory defect), not GLUT4-mediated skeletal muscle insulin resistance.
Option D: Option D is incorrect because somatostatin analogs suppress (not stimulate) glucagon via SSTR2; pasireotide does not cause hyperglucagonemia, and the hyperglycemia is due to insulin suppression.
Option E: Option E is incorrect because the hyperglycemia is a receptor-mediated suppression of insulin secretion through SSTR5, not a direct cytotoxic destruction of beta cells.
8. [CASE 2 — QUESTION 8]
Continuing with the same patient. The endocrinologist wishes to continue pasireotide because it has normalized her IGF-1, but must address the hyperglycemia. Which of the following pharmacologic choices is most mechanistically appropriate as first-line therapy for pasireotide-induced hyperglycemia, and why?
A) A sulfonylurea, because it directly closes beta-cell ATP-sensitive potassium channels and will reliably overcome the pasireotide effect regardless of the cAMP-dependent secretory block
B) An SGLT2 inhibitor as monotherapy, because pasireotide hyperglycemia is driven entirely by increased renal glucose reabsorption
C) A GLP-1 receptor agonist (or DPP-4 inhibitor), because pasireotide impairs insulin secretion through an SSTR5-mediated reduction in beta-cell cAMP, and GLP-1 receptor signaling raises beta-cell cAMP through a pathway that bypasses the somatostatin-inhibited step, restoring glucose-stimulated insulin secretion in a mechanistically targeted way
D) High-dose insulin glargine alone, because pasireotide causes irreversible beta-cell destruction that makes endogenous insulin secretion impossible to recover
E) Metformin is contraindicated and no oral agent can be used, so pasireotide must be discontinued immediately despite its efficacy
ANSWER: C
Rationale:
This question asked you to choose the most mechanistically appropriate first-line therapy for pasireotide-induced hyperglycemia. Pasireotide impairs insulin secretion through SSTR5-mediated Gi activation that lowers beta-cell cAMP. GLP-1 receptor agonists (and DPP-4 inhibitors, which raise endogenous GLP-1) act on the beta-cell GLP-1 receptor to raise cAMP through a pathway that bypasses the somatostatin-inhibited step, restoring glucose-stimulated insulin secretion in a directly targeted way. Clinical data support incretin-based therapy as particularly effective for pasireotide-associated hyperglycemia, which is why GLP-1 receptor agonists (or DPP-4 inhibitors) are favored first-line, with metformin as a common addition.
Option A: Option A is incorrect because, although a sulfonylurea also closes beta-cell potassium channels, incretin-based therapy that restores the cAMP-dependent secretory pathway is the more mechanistically targeted first choice; sulfonylureas are generally considered later and act less specifically against the pasireotide defect.
Option B: Option B is incorrect because pasireotide hyperglycemia is driven by impaired insulin secretion, not increased renal glucose reabsorption; an SGLT2 inhibitor does not address the underlying secretory defect as first-line monotherapy.
Option D: Option D is incorrect because pasireotide does not cause irreversible beta-cell destruction; the secretory suppression is receptor-mediated and reversible, so endogenous insulin secretion can be supported with incretin therapy rather than requiring insulin alone.
Option E: Option E is incorrect because metformin is not contraindicated and oral/incretin agents are effective; pasireotide does not need to be discontinued solely because of manageable hyperglycemia.
9. [CASE 3 — QUESTION 9]
A 45-year-old woman presents with central obesity, facial plethora, proximal muscle weakness, easy bruising, and new hypertension and glucose intolerance. Screening confirms hypercortisolism (elevated late-night salivary cortisol and failure to suppress on low-dose dexamethasone). To localize the cause, the first essential step is to determine whether the hypercortisolism is ACTH-dependent or ACTH-independent. Which of the following correctly describes how the plasma ACTH level distinguishes these two categories?
A) A suppressed (low) plasma ACTH indicates an ACTH-dependent process, because the pituitary has stopped producing ACTH in response to a pituitary adenoma
B) Plasma ACTH cannot distinguish ACTH-dependent from ACTH-independent Cushing syndrome; only urinary free cortisol can make this distinction
C) An elevated plasma ACTH always indicates an adrenal tumor producing both cortisol and ACTH simultaneously
D) A normal plasma ACTH excludes Cushing syndrome entirely, regardless of the cortisol level
E) A non-suppressed or elevated plasma ACTH indicates ACTH-dependent Cushing syndrome (a pituitary corticotroph adenoma or an ectopic ACTH source driving cortisol production), whereas a suppressed (low) plasma ACTH indicates ACTH-independent Cushing syndrome (autonomous adrenal cortisol production suppressing pituitary ACTH through negative feedback)
ANSWER: E
Rationale:
This question asked you to explain how plasma ACTH distinguishes ACTH-dependent from ACTH-independent Cushing syndrome. The plasma ACTH level is the pivotal branch point. A non-suppressed or elevated plasma ACTH indicates ACTH-dependent Cushing syndrome, in which ACTH (from a pituitary corticotroph adenoma — Cushing disease — or from an ectopic ACTH-secreting tumor) drives adrenal cortisol production. A suppressed (low) plasma ACTH indicates ACTH-independent Cushing syndrome, in which an autonomous adrenal source produces cortisol that suppresses pituitary ACTH through negative feedback. This ACTH-dependent versus ACTH-independent determination guides all subsequent localization studies.
Option A: Option A is incorrect because it inverts the relationship — a suppressed (low) ACTH indicates an ACTH-independent (adrenal) process, not an ACTH-dependent one.
Option B: Option B is incorrect because plasma ACTH is precisely the test that distinguishes the two categories; urinary free cortisol establishes the presence of hypercortisolism but does not localize the source.
Option C: Option C is incorrect because an elevated ACTH indicates an ACTH-dependent source (pituitary or ectopic), not an adrenal tumor; adrenal tumors are ACTH-independent and suppress ACTH.
Option D: Option D is incorrect because a normal ACTH does not exclude Cushing syndrome; in ACTH-dependent disease ACTH is often non-suppressed (within or above the reference range), and the diagnosis rests on the cortisol abnormalities together with ACTH interpretation.
10. [CASE 3 — QUESTION 10]
Continuing with the same patient. Her plasma ACTH is non-suppressed, confirming ACTH-dependent Cushing syndrome. To help distinguish a pituitary source from an ectopic ACTH source, she undergoes a CRH stimulation test. After intravenous CRH, her plasma ACTH rises by more than 50% above baseline with a corresponding cortisol rise. Which of the following best interprets this response?
A) The exaggerated ACTH rise indicates an ectopic ACTH-secreting tumor, because ectopic tumors are uniquely hyper-responsive to exogenous CRH
B) The exaggerated ACTH rise after CRH is most consistent with a pituitary corticotroph adenoma (Cushing disease), because the adenoma retains CRH-R1 responsiveness and amplifies ACTH secretion in response to exogenous CRH; ectopic ACTH sources typically lack functional CRH-R1 and usually show little or no response
C) The exaggerated ACTH rise indicates an adrenal adenoma, because autonomous adrenal cortisol sensitizes the pituitary to CRH
D) The exaggerated ACTH rise is a nonspecific finding seen equally in pituitary, ectopic, and adrenal causes and provides no localizing information
E) The exaggerated ACTH rise excludes a pituitary source, because pituitary adenomas secrete ACTH autonomously and cannot respond further to CRH
ANSWER: B
Rationale:
This question asked you to interpret an exaggerated ACTH response to CRH in ACTH-dependent Cushing syndrome. Pituitary corticotroph adenomas (Cushing disease) retain partial CRH-R1 responsiveness, so exogenous CRH produces an exaggerated ACTH rise (typically more than 35 to 50% above baseline) with a corresponding cortisol rise. Ectopic ACTH-secreting tumors usually lack functional CRH-R1 and therefore typically show little or no ACTH response to CRH. An exaggerated response thus favors a pituitary source, though confirmation often requires inferior petrosal sinus sampling.
Option A: Option A is incorrect because ectopic tumors are characteristically CRH-unresponsive, not hyper-responsive; the exaggerated response points to a pituitary source.
Option C: Option C is incorrect because an adrenal adenoma is ACTH-independent and suppresses pituitary ACTH; it would not produce an exaggerated ACTH rise to CRH, and the case has already established ACTH-dependent disease.
Option D: Option D is incorrect because the CRH response is not nonspecific — it helps distinguish pituitary (exaggerated response) from ectopic (little/no response) sources, providing real localizing information.
Option E: Option E is incorrect because pituitary adenomas retain CRH-R1 responsiveness and do respond to CRH with an exaggerated rise; the response supports, rather than excludes, a pituitary source.
11. [CASE 3 — QUESTION 11]
Continuing with the same patient. Pituitary MRI shows no discrete adenoma. To definitively localize the ACTH source, she undergoes inferior petrosal sinus sampling (IPSS) with CRH stimulation. The simultaneously measured central (petrosal) ACTH greatly exceeds the peripheral ACTH, and the central value increases further after CRH. Which of the following best explains why IPSS is able to localize the source, and what this result indicates?
A) IPSS samples adrenal venous blood, and a high adrenal-to-peripheral gradient indicates an adrenal source of cortisol
B) IPSS measures urinary cortisol metabolites and localizes the source by their excretion pattern
C) A high peripheral-to-central ACTH ratio indicates a pituitary source, because pituitary ACTH is diluted in the systemic circulation before reaching the petrosal sinuses
D) The inferior petrosal sinuses drain the pituitary, so a high central (petrosal)-to-peripheral ACTH gradient — accentuated by CRH — indicates that the ACTH source is the pituitary (Cushing disease); an ectopic ACTH source would not produce a central gradient because it secretes ACTH into the systemic circulation rather than into the petrosal drainage
E) IPSS distinguishes the source by measuring cortisol, not ACTH, and only ectopic tumors produce a measurable petrosal cortisol gradient
ANSWER: D
Rationale:
This question asked you to explain how inferior petrosal sinus sampling localizes the ACTH source. The inferior petrosal sinuses drain venous blood from the pituitary, so sampling ACTH there and comparing it with simultaneous peripheral ACTH localizes the source anatomically. A high central (petrosal)-to-peripheral ACTH gradient — accentuated after CRH stimulation — indicates that the ACTH source is the pituitary (Cushing disease), because pituitary corticotroph ACTH drains into the petrosal sinuses and the adenoma responds to CRH. An ectopic ACTH-secreting tumor secretes into the systemic circulation and does not produce a central petrosal gradient. IPSS with CRH is the gold standard for distinguishing pituitary from ectopic ACTH when MRI is non-diagnostic.
Option A: Option A is incorrect because IPSS samples the petrosal sinuses draining the pituitary, not adrenal venous blood; it localizes ACTH (a pituitary/ectopic question), and the case is ACTH-dependent, not adrenal.
Option B: Option B is incorrect because IPSS measures plasma ACTH in petrosal versus peripheral blood, not urinary cortisol metabolites.
Option C: Option C is incorrect because it inverts the gradient — a high central-to-peripheral (not peripheral-to-central) ACTH ratio indicates a pituitary source.
Option E: Option E is incorrect because IPSS localizes by measuring the ACTH gradient, not cortisol; a central ACTH gradient indicates a pituitary (not ectopic) source.
12. [CASE 3 — QUESTION 12]
Continuing with the same patient. IPSS confirms a pituitary source (Cushing disease). She undergoes transsphenoidal surgery, but hypercortisolism persists postoperatively, and she is not an immediate candidate for repeat surgery. The endocrinologist considers pasireotide as medical therapy. Which of the following best explains the receptor-based rationale for using pasireotide specifically in Cushing disease?
A) Pituitary corticotroph adenomas in Cushing disease characteristically express SSTR5 more abundantly than SSTR2; pasireotide, with its high SSTR5 affinity as a pan-somatostatin-receptor agonist, suppresses ACTH secretion from these corticotroph adenomas, which is why it is approved for Cushing disease whereas SSTR2-selective octreotide is generally ineffective
B) Corticotroph adenomas express only SSTR2, so octreotide is the preferred agent and pasireotide offers no advantage in Cushing disease
C) Pasireotide treats Cushing disease by directly antagonizing the adrenal cortisol-synthesizing enzymes, independent of any pituitary receptor
D) Pasireotide works in Cushing disease by blocking CRH-R1 on corticotroph cells, preventing CRH-driven ACTH release
E) Pasireotide lowers cortisol in Cushing disease by stimulating dopamine D2 receptors on corticotroph adenoma cells, a mechanism unique among somatostatin analogs
ANSWER: A
Rationale:
This question asked you to explain the receptor rationale for pasireotide in Cushing disease. Pituitary corticotroph adenomas characteristically express SSTR5 more abundantly than SSTR2. Pasireotide is a pan-somatostatin-receptor agonist with high SSTR5 affinity, so it can engage the SSTR5-rich corticotroph adenoma and suppress ACTH secretion — which is why pasireotide is approved for Cushing disease, whereas SSTR2-selective octreotide is generally ineffective because these tumors are relatively SSTR2-poor. This same SSTR5 engagement on pancreatic beta cells accounts for pasireotide's notable hyperglycemia liability.
Option B: Option B is incorrect because corticotroph adenomas express SSTR5 more than SSTR2, so octreotide (SSTR2-selective) is generally ineffective and pasireotide offers a clear advantage.
Option C: Option C is incorrect because pasireotide acts at pituitary corticotroph somatostatin receptors to suppress ACTH, not by directly inhibiting adrenal steroidogenic enzymes (that is the mechanism of agents such as ketoconazole, metyrapone, or osilodrostat).
Option D: Option D is incorrect because pasireotide is a somatostatin receptor agonist, not a CRH-R1 antagonist; it suppresses ACTH via SSTR5 agonism, not by blocking CRH receptors.
Option E: Option E is incorrect because pasireotide does not act through dopamine D2 receptors; cabergoline is the dopamine agonist sometimes used in Cushing disease, and pasireotide's mechanism is SSTR5 agonism.
13. [CASE 4 — QUESTION 13]
A 40-year-old woman undergoes transsphenoidal resection of a large craniopharyngioma. On postoperative day 1 she develops polyuria (urine output 9 L/day), intense thirst, and rising serum sodium (148 mEq/L) with elevated serum osmolality. Her urine is inappropriately dilute (low urine osmolality) despite the hyperosmolar plasma. Which of the following is the most likely diagnosis and its mechanism?
A) SIADH from surgical irritation, with water retention causing the elevated serum sodium
B) Cerebral salt wasting, with renal sodium loss producing the polyuria and dilute urine
C) Central (neurogenic) diabetes insipidus from surgical disruption of hypothalamic/posterior pituitary vasopressin (ADH) production or release; the resulting ADH deficiency prevents renal water reabsorption, producing dilute urine, polyuria, hypernatremia, and elevated serum osmolality
D) Osmotic diuresis from postoperative hyperglycemia, with glucosuria driving the polyuria
E) Acute kidney injury with loss of urinary concentrating ability due to tubular necrosis
ANSWER: C
Rationale:
This question asked you to identify the cause of postoperative polyuria with hypernatremia and dilute urine after pituitary surgery. The picture — polyuria, intense thirst, hypernatremia, elevated serum osmolality, and inappropriately dilute urine — is classic for central (neurogenic) diabetes insipidus. Surgical manipulation near the hypothalamus and posterior pituitary disrupts vasopressin (ADH) production or release; the resulting ADH deficiency prevents the renal collecting duct from reabsorbing water (because aquaporin-2 insertion is not stimulated), producing large volumes of dilute urine and a rising serum sodium and osmolality.
Option A: Option A is incorrect because SIADH causes water retention with hyponatremia and concentrated urine — the opposite of this patient's hypernatremia and dilute urine.
Option B: Option B is incorrect because cerebral salt wasting produces hyponatremia with volume depletion, not the hypernatremia and dilute urine seen here.
Option D: Option D is incorrect because osmotic diuresis from hyperglycemia would produce glucosuria and an osmotically active urine, not the inappropriately dilute urine of ADH deficiency; the clinical pattern points to central diabetes insipidus.
Option E: Option E is incorrect because acute tubular necrosis typically presents with reduced urine output or isosthenuria and rising creatinine, not the massive dilute polyuria with hypernatremia characteristic of central diabetes insipidus.
14. [CASE 4 — QUESTION 14]
Continuing with the same patient. To confirm the diagnosis and distinguish central from nephrogenic diabetes insipidus, she is given a dose of desmopressin and the urine osmolality response is measured. Her urine osmolality rises substantially after desmopressin. Which of the following best explains this response and the distinction it establishes?
A) The rise in urine osmolality indicates nephrogenic diabetes insipidus, because the renal collecting duct is intrinsically unable to respond to vasopressin
B) The substantial rise in urine osmolality after desmopressin indicates central diabetes insipidus: the kidney's V2 receptors and aquaporin-2 machinery are intact and respond to the exogenous V2 agonist, confirming that the defect is a deficiency of ADH production rather than renal unresponsiveness; in nephrogenic diabetes insipidus the urine would fail to concentrate because the renal response to vasopressin is impaired
C) The rise in urine osmolality indicates primary polydipsia, because desmopressin corrects excessive water intake
D) The rise in urine osmolality indicates that the patient never had diabetes insipidus, because any concentrating response excludes the diagnosis entirely
E) The rise in urine osmolality reflects desmopressin acting on V1a receptors to constrict renal vasculature and reduce urine flow, independent of water channel insertion
ANSWER: B
Rationale:
This question asked you to interpret the urine osmolality response to desmopressin in the differential of diabetes insipidus. Desmopressin is a selective V2 receptor agonist. In central (neurogenic) diabetes insipidus, the kidney's V2 receptors and aquaporin-2 machinery are intact — the problem is a deficiency of ADH production — so administering desmopressin drives aquaporin-2 insertion and produces a substantial rise in urine osmolality. In nephrogenic diabetes insipidus, the renal response to vasopressin is impaired (receptor or aquaporin defect), so the urine fails to concentrate after desmopressin. The robust concentrating response therefore confirms central diabetes insipidus and distinguishes it from the nephrogenic form.
Option A: Option A is incorrect because a substantial concentrating response indicates an intact (responsive) kidney, which characterizes central — not nephrogenic — diabetes insipidus; in nephrogenic disease the urine fails to concentrate.
Option C: Option C is incorrect because the patient has true ADH-deficient diabetes insipidus with hypernatremia, not primary polydipsia; desmopressin does not "correct excessive water intake," and the concentrating response reflects intact renal V2 signaling.
Option D: Option D is incorrect because the concentrating response does not exclude diabetes insipidus — it confirms the central form; the diagnosis rests on the full clinical and biochemical picture, and the desmopressin response distinguishes central from nephrogenic.
Option E: Option E is incorrect because desmopressin has negligible V1a activity and concentrates urine through V2-mediated aquaporin-2 insertion, not through V1a-mediated renal vasoconstriction.
15. [CASE 4 — QUESTION 15]
Continuing with the same patient. She is established on intranasal desmopressin for long-term management of her central diabetes insipidus. Her family asks why desmopressin, rather than native vasopressin, is used for chronic outpatient therapy. Which of the following best explains the pharmacologic advantage of desmopressin for chronic use?
A) Desmopressin has a shorter duration of action than vasopressin, requiring frequent dosing that allows finer control but no other advantage
B) Desmopressin is a non-selective V1/V2 agonist identical to vasopressin, and the only difference is its lower cost
C) Desmopressin is a V2 receptor antagonist that prevents water reabsorption, which is paradoxically beneficial in diabetes insipidus
D) Desmopressin acts centrally to restore hypothalamic ADH synthesis, curing the underlying deficiency rather than replacing the hormone
E) Desmopressin is engineered for selective V2 receptor agonism with negligible V1a activity, so it provides effective antidiuresis (V2-mediated aquaporin-2 insertion) without the vasoconstriction and blood pressure effects that native vasopressin produces through V1a activation, making it well suited to safe chronic outpatient use
ANSWER: E
Rationale:
This question asked you to explain why desmopressin is preferred over native vasopressin for chronic management of central diabetes insipidus. Desmopressin is a synthetic vasopressin analog engineered for selective V2 receptor agonism with negligible V1a activity. V2 agonism provides the needed antidiuresis through aquaporin-2 insertion in the renal collecting duct, while the absence of meaningful V1a activity means it avoids the vasoconstriction and blood pressure elevation that native vasopressin (a V1a plus V2 agonist) would cause. This receptor selectivity makes desmopressin safe and convenient for chronic outpatient replacement therapy.
Option A: Option A is incorrect because desmopressin actually has a longer, more convenient duration of action than native vasopressin, and the key advantage is its V2 selectivity, not a shorter duration.
Option B: Option B is incorrect because desmopressin is V2-selective with negligible V1a activity, not a non-selective V1/V2 agonist identical to vasopressin; the receptor selectivity (not merely cost) is its defining feature.
Option C: Option C is incorrect because desmopressin is a V2 agonist (not antagonist); it promotes water reabsorption to treat diabetes insipidus, and a V2 antagonist would worsen the condition.
Option D: Option D is incorrect because desmopressin replaces the hormone's action at the renal V2 receptor; it does not restore hypothalamic ADH synthesis or cure the underlying deficiency.
16. [CASE 4 — QUESTION 16]
Continuing with the same patient. Some months later she requires a minor dental procedure, and her hematologist notes that she has mild type 1 von Willebrand disease. The hematologist comments that desmopressin can serve a second, hemostatic purpose in addition to its antidiuretic role. Which of the following best explains the mechanism by which desmopressin provides hemostatic benefit?
A) Desmopressin, through V2 receptor activation on vascular endothelial cells, stimulates the release of von Willebrand factor (and factor VIII) from endothelial Weibel-Palade body stores into the plasma, transiently increasing their circulating levels and improving primary hemostasis in conditions such as mild von Willebrand disease and mild hemophilia A
B) Desmopressin directly activates platelets through a V1a receptor on the platelet surface, causing immediate aggregation independent of von Willebrand factor
C) Desmopressin provides hemostasis by promoting hepatic synthesis of all clotting factors over several days through a nuclear receptor mechanism
D) Desmopressin works as a hemostatic agent by causing vasoconstriction of bleeding vessels via potent V1a agonism, mechanically reducing blood loss
E) Desmopressin improves hemostasis by inhibiting fibrinolysis through direct blockade of plasminogen activation, unrelated to von Willebrand factor
ANSWER: A
Rationale:
This question asked you to explain desmopressin's hemostatic mechanism. Desmopressin acts on V2 receptors on vascular endothelial cells to stimulate the release of von Willebrand factor and factor VIII from endothelial Weibel-Palade body stores into the plasma. This transiently raises circulating von Willebrand factor and factor VIII levels, improving primary hemostasis — which is why desmopressin is used for procedures in patients with mild type 1 von Willebrand disease and mild hemophilia A. This hemostatic effect is a V2-mediated action distinct from but mechanistically related to its renal antidiuretic effect.
Option B: Option B is incorrect because desmopressin does not directly activate platelets through a platelet V1a receptor; its hemostatic benefit is mediated by V2-driven endothelial release of von Willebrand factor, which then supports platelet adhesion.
Option C: Option C is incorrect because desmopressin acts rapidly by releasing pre-stored von Willebrand factor and factor VIII from endothelial stores, not by promoting slow hepatic synthesis of all clotting factors through a nuclear receptor.
Option D: Option D is incorrect because desmopressin has negligible V1a activity and does not work hemostatically through vasoconstriction; its benefit is the V2-mediated release of von Willebrand factor and factor VIII.
Option E: Option E is incorrect because desmopressin does not act primarily as an antifibrinolytic that blocks plasminogen activation (that describes agents like tranexamic acid); its hemostatic mechanism is von Willebrand factor and factor VIII release.
17. [CASE 5 — QUESTION 17]
A 66-year-old man with small cell lung cancer is admitted with confusion and lethargy. Serum sodium is 116 mEq/L. He is clinically euvolemic (no edema, no orthostasis). Laboratory studies show low serum osmolality, inappropriately concentrated urine (high urine osmolality), and elevated urine sodium, with normal thyroid and adrenal function. Which of the following is the most likely diagnosis and its underlying mechanism?
A) Diabetes insipidus, with ADH deficiency producing the hyponatremia
B) Hypovolemic hyponatremia from gastrointestinal losses, with appropriate ADH-driven water retention
C) Psychogenic polydipsia, with excessive water intake overwhelming renal excretory capacity and maximally dilute urine
D) Syndrome of inappropriate antidiuretic hormone secretion (SIADH), most likely from ectopic ADH production by the small cell lung cancer; inappropriately elevated ADH drives renal water retention (via V2-mediated aquaporin-2 insertion) despite low serum osmolality, producing euvolemic hyponatremia with concentrated urine and elevated urine sodium
E) Hypervolemic hyponatremia from heart failure, with edema and reduced effective circulating volume
ANSWER: D
Rationale:
This question asked you to identify the cause of euvolemic hyponatremia with concentrated urine in a patient with small cell lung cancer. The findings — euvolemic hyponatremia, low serum osmolality, inappropriately concentrated urine, elevated urine sodium, and normal thyroid and adrenal function — are diagnostic of SIADH. In this patient, the most likely source is ectopic ADH production by the small cell lung cancer. Inappropriately elevated ADH acts on renal collecting duct V2 receptors to drive aquaporin-2-mediated water retention despite the already low serum osmolality, producing dilutional hyponatremia with concentrated urine. Small cell lung cancer is a classic cause of ectopic ADH secretion.
Option A: Option A is incorrect because diabetes insipidus causes hypernatremia with dilute urine from ADH deficiency — the opposite of this patient's hyponatremia with concentrated urine.
Option B: Option B is incorrect because the patient is clinically euvolemic, not hypovolemic, and SIADH (not volume depletion) explains the concentrated urine with elevated urine sodium.
Option C: Option C is incorrect because psychogenic polydipsia produces maximally dilute (not concentrated) urine as the kidney excretes the water load; this patient's urine is inappropriately concentrated.
Option E: Option E is incorrect because hypervolemic hyponatremia from heart failure presents with edema and signs of volume overload, whereas this patient is euvolemic, consistent with SIADH rather than a hypervolemic state.
18. [CASE 5 — QUESTION 18]
Continuing with the same patient. Fluid restriction provides inadequate correction of his hyponatremia, and the team initiates tolvaptan. Which of the following correctly describes tolvaptan's mechanism of action?
A) Tolvaptan is a selective V2 receptor agonist that enhances aquaporin-2 insertion, increasing water reabsorption to dilute excess sodium
B) Tolvaptan is a somatostatin analog that suppresses ectopic ADH production by the tumor through SSTR2 agonism
C) Tolvaptan is a selective vasopressin V2 receptor antagonist; by blocking V2 receptors on renal collecting duct principal cells, it prevents ADH-stimulated aquaporin-2 insertion, reducing water reabsorption and producing a free water diuresis (aquaresis) that raises serum sodium
D) Tolvaptan is a V1a receptor antagonist that produces vasodilation and incidentally increases renal blood flow to correct hyponatremia
E) Tolvaptan is a loop diuretic that increases excretion of both sodium and water equally, correcting hyponatremia through volume contraction
ANSWER: C
Rationale:
This question asked you to identify tolvaptan's mechanism in treating SIADH. Tolvaptan is a selective vasopressin V2 receptor antagonist. By blocking V2 receptors on renal collecting duct principal cells, it prevents ADH-stimulated aquaporin-2 water channel insertion, reducing water reabsorption and producing a free water diuresis (aquaresis) — excretion of water out of proportion to electrolytes — which raises serum sodium and corrects the dilutional hyponatremia of SIADH.
Option A: Option A is incorrect because tolvaptan is a V2 antagonist, not an agonist; it reduces (not enhances) water reabsorption, which is what raises serum sodium.
Option B: Option B is incorrect because tolvaptan is not a somatostatin analog and does not suppress tumor ADH production; it blocks the renal V2 receptor downstream of ADH.
Option D: Option D is incorrect because tolvaptan is a V2 antagonist, not a V1a antagonist; its therapeutic action is renal aquaresis, not vasodilation-mediated changes in renal blood flow.
Option E: Option E is incorrect because tolvaptan is a vaptan (V2 antagonist), not a loop diuretic; it produces a selective water diuresis (aquaresis) rather than the combined sodium and water loss of a loop diuretic.
19. [CASE 5 — QUESTION 19]
Continuing with the same patient. Before and during tolvaptan therapy, the team emphasizes one monitoring parameter as the most critical safety concern. Which of the following is the single most important concern during tolvaptan initiation, and what is the underlying risk?
A) Hyperkalemia, because tolvaptan retains potassium as it excretes water, risking fatal arrhythmia
B) Acute hypotension, because tolvaptan causes profound vasodilation through V1a blockade
C) Profound hypoglycemia, because tolvaptan suppresses pancreatic insulin secretion like a somatostatin analog
D) Hypernatremia-induced cerebral edema, because tolvaptan causes water retention that swells brain cells
E) Overly rapid correction of serum sodium, because a too-rapid rise (generally exceeding about 8 to 10 mEq/L in 24 hours) risks osmotic demyelination syndrome; the rate of sodium rise must be monitored closely, fluid restriction is typically relaxed during therapy, and tolvaptan is initiated in a monitored setting
ANSWER: E
Rationale:
This question asked you to identify the most important safety concern during tolvaptan initiation. Tolvaptan can correct hyponatremia rapidly by producing a brisk free water diuresis, so the single most important concern is overly rapid correction of serum sodium. Raising serum sodium too quickly (generally more than about 8 to 10 mEq/L in 24 hours) risks osmotic demyelination syndrome (central pontine myelinolysis), a devastating neurologic injury. Therefore the rate of sodium correction must be monitored closely, fluid restriction is typically relaxed during tolvaptan therapy to avoid additive overcorrection, and the drug is started in a monitored inpatient setting.
Option A: Option A is incorrect because hyperkalemia is not the principal concern with tolvaptan; it produces a water diuresis, and dangerous potassium retention is not its characteristic risk.
Option B: Option B is incorrect because tolvaptan is a V2 (not V1a) antagonist and does not cause profound vasodilation-mediated hypotension as its main safety issue.
Option C: Option C is incorrect because tolvaptan is not a somatostatin analog and does not suppress insulin secretion; hypoglycemia is not its concern.
Option D: Option D is incorrect because tolvaptan causes water excretion (raising sodium), not water retention; the risk is too-rapid correction toward and beyond normal sodium, not hypernatremia-induced cerebral edema from water retention.
20. [CASE 5 — QUESTION 20]
Continuing with the same patient. A trainee asks how conivaptan differs from tolvaptan, since both are vaptans used for hyponatremia. Which of the following correctly distinguishes the two agents?
A) Conivaptan is an oral selective V2 antagonist, while tolvaptan is an intravenous non-selective V1a/V2 antagonist; their selectivity profiles are the reverse of what is commonly stated
B) Tolvaptan is an oral selective V2 receptor antagonist, whereas conivaptan is an intravenous non-selective antagonist that blocks both V1a and V2 receptors; both produce aquaresis through V2 blockade, but conivaptan's additional V1a antagonism distinguishes its receptor profile
C) Conivaptan and tolvaptan are both V2 receptor agonists that differ only in route of administration
D) Conivaptan is a somatostatin analog and tolvaptan is a V2 antagonist, so they act through entirely different receptor families
E) Tolvaptan blocks oxytocin receptors while conivaptan blocks vasopressin receptors, so only conivaptan is a true vaptan
ANSWER: B
Rationale:
This question asked you to distinguish conivaptan from tolvaptan. Both are vaptans (vasopressin receptor antagonists) used for hyponatremia, and both produce aquaresis by blocking renal V2 receptors. The key difference is selectivity and administration: tolvaptan is an oral selective V2 receptor antagonist, whereas conivaptan is an intravenous non-selective antagonist that blocks both V1a and V2 receptors. Conivaptan's additional V1a antagonism is the feature that distinguishes its receptor profile from the V2-selective tolvaptan.
Option A: Option A is incorrect because it reverses the profiles — tolvaptan is the oral V2-selective agent, and conivaptan is the intravenous non-selective V1a/V2 agent, not the other way around.
Option C: Option C is incorrect because conivaptan and tolvaptan are V2 antagonists, not agonists; agonism would worsen hyponatremia.
Option D: Option D is incorrect because conivaptan is a vasopressin receptor antagonist (vaptan), not a somatostatin analog; both agents act within the vasopressin receptor family.
Option E: Option E is incorrect because both tolvaptan and conivaptan are vasopressin receptor antagonists (vaptans); neither is primarily an oxytocin receptor blocker, and both block vasopressin receptors.
21. [CASE 6 — QUESTION 21]
A 32-year-old woman with biopsy-confirmed endometriosis has severe dysmenorrhea and chronic pelvic pain inadequately controlled with NSAIDs and combined oral contraceptives. Her gynecologist starts elagolix, an oral GnRH receptor antagonist. Which of the following best describes elagolix and its initial effect on the hypothalamic-pituitary-gonadal axis?
A) Elagolix is a non-peptide, orally bioavailable GnRH receptor antagonist that competitively blocks the GnRH receptor on pituitary gonadotrophs, producing immediate, dose-dependent suppression of LH and FSH and consequently of ovarian estrogen — without the initial hormonal flare characteristic of GnRH agonists
B) Elagolix is a peptide GnRH agonist that must be injected and produces an initial estrogen surge before downregulation suppresses the axis
C) Elagolix is a selective estrogen receptor modulator that blocks estrogen at endometrial tissue without affecting the hypothalamic-pituitary-gonadal axis
D) Elagolix is an aromatase inhibitor that blocks peripheral estrogen synthesis and has no direct effect on pituitary gonadotropin secretion
E) Elagolix is a progestin that suppresses endometriosis by directly thinning the endometrium, independent of any GnRH receptor activity
ANSWER: A
Rationale:
This question asked you to characterize elagolix and its initial axis effect. Elagolix is a non-peptide, orally bioavailable GnRH receptor antagonist. It competitively blocks the GnRH receptor on pituitary gonadotrophs, producing immediate, dose-dependent suppression of LH and FSH and a consequent fall in ovarian estrogen. Because it blocks (rather than transiently activates) the receptor, it does not cause the initial hormonal flare seen with GnRH agonists — an advantage for prompt symptom control in estrogen-dependent endometriosis. Its dose-dependent suppression allows partial or fuller axis suppression depending on the regimen.
Option B: Option B is incorrect because elagolix is a non-peptide oral antagonist, not an injectable peptide agonist, and it does not produce an initial estrogen surge; antagonists suppress immediately without a flare.
Option C: Option C is incorrect because elagolix acts at the pituitary GnRH receptor to suppress the axis, not as a selective estrogen receptor modulator acting only at endometrial tissue.
Option D: Option D is incorrect because elagolix is a GnRH receptor antagonist acting at the pituitary, not an aromatase inhibitor; it directly suppresses gonadotropin secretion.
Option E: Option E is incorrect because elagolix is not a progestin and does not act by directly thinning the endometrium independent of GnRH; it lowers estrogen by blocking the GnRH receptor and suppressing the axis.
22. [CASE 6 — QUESTION 22]
Continuing with the same patient. Her gynecologist explains that elagolix can be dosed to achieve either partial or fuller suppression of estrogen, and that the choice involves a trade-off. Which of the following best explains the pharmacologic basis and clinical trade-off of elagolix's dose-dependent estrogen suppression?
A) Elagolix produces all-or-none estrogen suppression regardless of dose, so there is no meaningful trade-off between doses
B) Higher elagolix doses paradoxically raise estrogen by stimulating the GnRH receptor, so lower doses are always preferred for endometriosis
C) Because elagolix competitively and dose-dependently blocks the GnRH receptor, lower doses produce partial estrogen suppression (often sufficient for pain control while preserving some estrogen to limit bone loss and vasomotor symptoms), whereas higher doses produce fuller estrogen suppression (greater efficacy for severe pain but more hypoestrogenic effects such as hot flashes and bone mineral density loss), so dosing is chosen to balance symptom control against hypoestrogenic adverse effects and duration of therapy
D) Elagolix dose affects only the duration of action but not the degree of estrogen suppression, which is fixed at a single level
E) The dose-dependence reflects elagolix acting as a partial agonist that increases estrogen at low doses and decreases it at high doses
ANSWER: C
Rationale:
This question asked you to explain the pharmacologic basis and clinical trade-off of elagolix's dose-dependent estrogen suppression. Elagolix competitively and dose-dependently blocks the pituitary GnRH receptor, so the degree of axis suppression scales with dose. Lower doses produce partial estrogen suppression — often sufficient for pain control while preserving enough estrogen to limit bone mineral density loss and vasomotor symptoms — whereas higher doses produce fuller estrogen suppression with greater efficacy for severe pain but more hypoestrogenic adverse effects (hot flashes, bone loss). Dosing is therefore selected to balance symptom control against hypoestrogenic effects and the intended duration of therapy, and treatment duration is limited because of cumulative bone density concerns.
Option A: Option A is incorrect because elagolix produces graded, dose-dependent (not all-or-none) suppression, and there is a real trade-off between doses.
Option B: Option B is incorrect because higher doses do not paradoxically raise estrogen; as a competitive antagonist, higher doses produce greater (not lesser) suppression.
Option D: Option D is incorrect because elagolix dose affects the degree of estrogen suppression, not merely duration; the suppression is graded by dose.
Option E: Option E is incorrect because elagolix is a competitive antagonist, not a partial agonist; it does not increase estrogen at low doses — it produces partial suppression at low doses and fuller suppression at higher doses.
23. [CASE 6 — QUESTION 23]
Continuing with the same patient. After months of good control on elagolix, she is started on a strong CYP3A4 inducer for a new medical condition, and her pelvic pain gradually returns despite continued adherence. Which of the following best explains the loss of efficacy?
A) The CYP3A4 inducer displaced elagolix from plasma proteins, lowering total drug levels but not free drug, so efficacy should be unchanged
B) The CYP3A4 inducer inhibited elagolix metabolism, raising its concentration and causing receptor desensitization that restored estrogen production
C) The CYP3A4 inducer converted elagolix into an active agonist metabolite that now stimulates the gonadal axis
D) Elagolix is metabolized predominantly by CYP3A4; a strong CYP3A4 inducer accelerates its metabolism, lowering plasma elagolix concentrations and reducing its suppression of the hypothalamic-pituitary-gonadal axis, allowing estrogen to rise and estrogen-dependent endometriosis pain to recur
E) The recurrence is unrelated to the inducer and proves that elagolix inevitably loses effect through GnRH receptor downregulation over time
ANSWER: D
Rationale:
This question asked you to explain the loss of elagolix efficacy after starting a CYP3A4 inducer. Elagolix is metabolized predominantly by CYP3A4 (with a secondary contribution from CYP2C8). A strong CYP3A4 inducer increases hepatic CYP3A4 activity, accelerating elagolix metabolism and lowering its plasma concentration. Reduced elagolix exposure means less suppression of the hypothalamic-pituitary-gonadal axis, so estrogen rises and estrogen-dependent endometriosis pain recurs — exactly the described pattern. Recognizing this interaction directs management toward reassessing the interacting drug or the GnRH-axis therapy rather than assuming disease progression.
Option A: Option A is incorrect because the dominant interaction is CYP3A4 induction increasing metabolism, not plasma protein displacement; induction genuinely lowers drug exposure and reduces efficacy.
Option B: Option B is incorrect because an inducer accelerates (not inhibits) elagolix metabolism, lowering — not raising — its concentration.
Option C: Option C is incorrect because elagolix is a GnRH antagonist and is not converted into an active agonist metabolite; CYP3A4 metabolism yields inactive metabolites, so induction reduces active drug.
Option E: Option E is incorrect because the recurrence is explained by the CYP3A4 inducer reducing elagolix levels, not by intrinsic GnRH receptor downregulation; the interaction is the cause.
24. [CASE 6 — QUESTION 24]
Continuing with the same patient. After the interacting medication is changed, she resumes effective elagolix therapy. Because she may need prolonged treatment, her gynecologist discusses strategies to mitigate the hypoestrogenic adverse effects of sustained GnRH-axis suppression. Which of the following best explains the rationale for hormonal "add-back" therapy in this setting?
A) Add-back therapy consists of administering a GnRH agonist alongside elagolix to deepen axis suppression and improve efficacy
B) Sustained suppression of ovarian estrogen by elagolix produces a hypoestrogenic state that causes vasomotor symptoms and progressive bone mineral density loss; low-dose hormonal "add-back" (for example, a small amount of estrogen with a progestin, as used with GnRH agonists) restores just enough estrogen to mitigate these hypoestrogenic effects and permit longer-duration therapy, while leaving enough estrogen suppression to maintain control of the estrogen-dependent endometriosis
C) Add-back therapy provides high-dose estrogen to fully restore premenopausal estrogen levels, which does not interfere with endometriosis control because elagolix blocks estrogen at the endometrium directly
D) Add-back therapy is used to counteract hyperestrogenism caused by elagolix, since GnRH antagonists raise estrogen over time
E) Add-back therapy consists of calcium and vitamin D alone and addresses vasomotor symptoms through a direct effect on the hypothalamic thermoregulatory center
ANSWER: B
Rationale:
This question asked you to explain the rationale for hormonal add-back therapy with sustained GnRH-axis suppression. Elagolix lowers ovarian estrogen, and sustained hypoestrogenism produces vasomotor symptoms (hot flashes) and progressive bone mineral density loss, which limit the duration of therapy. Low-dose hormonal add-back — a small amount of estrogen combined with a progestin, analogous to the strategy used with GnRH agonists — restores just enough estrogen to mitigate the hypoestrogenic adverse effects and permit longer treatment, while leaving sufficient estrogen suppression to maintain control of the estrogen-dependent endometriosis. The concept relies on the threshold hypothesis: a level of estrogen low enough to control endometriosis but high enough to protect bone and reduce vasomotor symptoms.
Option A: Option A is incorrect because add-back is not a GnRH agonist given to deepen suppression; it is low-dose hormonal replacement to offset hypoestrogenic effects.
Option C: Option C is incorrect because add-back uses low-dose (not high-dose) hormone to avoid fully restoring estrogen, which would stimulate the endometriosis; elagolix lowers systemic estrogen by suppressing the axis rather than blocking estrogen at the endometrium directly.
Option D: Option D is incorrect because elagolix lowers (not raises) estrogen; the issue addressed by add-back is hypoestrogenism, not hyperestrogenism.
Option E: Option E is incorrect because add-back therapy centers on low-dose estrogen-progestin replacement; while calcium and vitamin D support bone health, they do not constitute the add-back strategy and do not act on the hypothalamic thermoregulatory center to relieve vasomotor symptoms.
25. [CASE 7 — QUESTION 25]
A 34-year-old woman presents with galactorrhea, oligomenorrhea, fatigue, cold intolerance, and weight gain. Laboratory testing shows TSH 76 mIU/L, markedly low free T4, and prolactin 58 ng/mL (moderately elevated). Pituitary MRI shows mild symmetric pituitary enlargement without a discrete adenoma. Which of the following best explains the mechanism linking her hypothyroidism to her hyperprolactinemia?
A) Severe hypothyroidism reduces hepatic clearance of prolactin, raising circulating prolactin levels without any hypothalamic-pituitary mechanism
B) Low thyroid hormone directly binds lactotroph nuclear receptors and upregulates the prolactin gene independent of any hypothalamic input
C) Elevated TSH cross-reacts with the prolactin receptor on lactotroph cells, acting as a partial agonist to stimulate prolactin secretion
D) Hypothyroidism increases hypothalamic dopamine output, which paradoxically stimulates prolactin secretion at the lactotroph
E) In severe primary hypothyroidism, the loss of thyroid hormone negative feedback drives chronically elevated TRH; because the TRH receptor is expressed on lactotrophs as well as thyrotrophs, the high TRH directly stimulates prolactin secretion, producing hyperprolactinemia and galactorrhea, while chronic thyrotroph/lactotroph stimulation causes the reactive pituitary enlargement
ANSWER: E
Rationale:
This question asked you to explain the mechanism linking primary hypothyroidism to hyperprolactinemia. In severe primary hypothyroidism, the loss of thyroid hormone negative feedback drives chronically elevated TRH secretion. The TRH receptor is expressed on lactotrophs as well as thyrotrophs, so high TRH directly stimulates prolactin secretion (in addition to driving the elevated TSH), producing hyperprolactinemia with galactorrhea and oligomenorrhea. Chronic stimulation of thyrotrophs and lactotrophs also causes reactive pituitary hyperplasia that appears as symmetric pituitary enlargement on MRI, mimicking an adenoma. This mechanism is reversible with thyroid hormone replacement.
Option A: Option A is incorrect because the hyperprolactinemia is primarily due to increased TRH-driven secretion, not reduced hepatic clearance; the resolution with levothyroxine operates through restored feedback on TRH.
Option B: Option B is incorrect because low thyroid hormone does not directly upregulate the prolactin gene via lactotroph nuclear receptors; the elevation is mediated by TRH stimulation of lactotrophs.
Option C: Option C is incorrect because TSH does not cross-react with the prolactin receptor at clinically relevant levels; the mechanism is TRH stimulation, not TSH-prolactin receptor cross-reactivity.
Option D: Option D is incorrect because hypothyroidism does not increase dopamine output to stimulate prolactin — dopamine inhibits prolactin — and the mechanism here is TRH-driven stimulation, not altered dopaminergic tone.
26. [CASE 7 — QUESTION 26]
Continuing with the same patient. Her endocrinologist elects to treat the underlying disorder first and predicts that both the hyperprolactinemia and the pituitary enlargement will resolve without prolactin-directed therapy or surgery. Which of the following is the most appropriate initial treatment, and why?
A) Levothyroxine, because restoring thyroid hormone re-establishes negative feedback on the hypothalamus, lowers the chronically elevated TRH drive, and thereby resolves both the TRH-driven hyperprolactinemia and the reactive thyrotroph/lactotroph hyperplasia (pituitary enlargement) without the need for a dopamine agonist or surgery
B) Transsphenoidal surgery, because the symmetric pituitary enlargement represents a prolactinoma that requires resection
C) Cabergoline, because dopamine agonist therapy is the definitive treatment for all causes of hyperprolactinemia regardless of etiology
D) A somatostatin analog, because somatostatin is the primary inhibitor of prolactin and will normalize the level
E) Pituitary irradiation, because the combination of enlargement and hyperprolactinemia indicates an aggressive tumor unresponsive to medical therapy
ANSWER: A
Rationale:
This question asked you to select the most appropriate initial treatment for hyperprolactinemia driven by primary hypothyroidism. The correct step is levothyroxine to treat the underlying hypothyroidism. Restoring thyroid hormone re-establishes negative feedback on the hypothalamus, lowering the chronically elevated TRH drive that was stimulating lactotrophs. This resolves the TRH-driven hyperprolactinemia and the reactive thyrotroph/lactotroph hyperplasia (the symmetric pituitary enlargement) without a dopamine agonist or surgery. Recognizing the TRH-driven mechanism prevents unnecessary intervention.
Option B: Option B is incorrect because the pituitary enlargement is reactive hyperplasia, not a prolactinoma; surgery is unnecessary, and treating the hypothyroidism resolves the findings.
Option C: Option C is incorrect because cabergoline is not the appropriate first treatment here; the hyperprolactinemia is secondary to hypothyroidism and resolves with levothyroxine, and dopamine agonists are not indicated for TRH-driven hyperprolactinemia of this kind.
Option D: Option D is incorrect because somatostatin is not the primary inhibitor of prolactin (dopamine is), and somatostatin analogs are not used to treat this condition; levothyroxine is the correct therapy.
Option E: Option E is incorrect because the imaging reflects benign reactive hyperplasia, not an aggressive tumor; irradiation is not indicated, and the condition responds to thyroid hormone replacement.
27. [CASE 7 — QUESTION 27]
Continuing with the same patient. After several months of levothyroxine, her thyroid function normalizes, but her prolactin remains elevated and galactorrhea persists. On careful medication review, she discloses she was started on risperidone for a mood disorder around the time her symptoms failed to resolve. Which of the following best explains the persistent hyperprolactinemia?
A) The persistent hyperprolactinemia proves that levothyroxine was ineffective and the original diagnosis of hypothyroidism-related hyperprolactinemia was incorrect
B) Risperidone lowers prolactin through 5-HT2A antagonism, so it cannot be responsible; the persistence indicates an undiagnosed prolactinoma
C) Risperidone is a potent dopamine D2 receptor antagonist that blocks D2 receptors on pituitary lactotrophs, removing dopaminergic inhibition of prolactin secretion; this drug-induced hyperprolactinemia is now the operative cause, superimposed on the resolved hypothyroidism, explaining why the prolactin remained elevated after thyroid normalization
D) Risperidone elevates prolactin by stimulating TRH secretion, the same mechanism as the original hypothyroidism
E) Risperidone elevates prolactin by directly activating prolactin receptors on lactotrophs as a partial agonist
ANSWER: C
Rationale:
This question asked you to explain persistent hyperprolactinemia after the hypothyroidism resolved. With thyroid function now normalized, the original TRH-driven mechanism should have resolved, so a new cause must be operative. Risperidone is a potent dopamine D2 receptor antagonist; by blocking D2 receptors on pituitary lactotrophs, it removes the tonic dopaminergic inhibition of prolactin secretion, producing drug-induced hyperprolactinemia. This antipsychotic-induced hyperprolactinemia, superimposed on the now-resolved hypothyroidism, explains why the prolactin remained elevated and galactorrhea persisted after thyroid normalization. Recognizing the timing (symptoms persisting after risperidone was started) identifies the new cause.
Option A: Option A is incorrect because the persistence does not prove levothyroxine failed; thyroid function normalized, and a new cause (risperidone) accounts for the ongoing hyperprolactinemia.
Option B: Option B is incorrect because risperidone raises (not lowers) prolactin — it is one of the most prolactin-elevating antipsychotics due to potent D2 blockade; its 5-HT2A antagonism does not prevent the prolactin elevation.
Option D: Option D is incorrect because risperidone elevates prolactin by direct D2 receptor blockade at the pituitary, not by stimulating TRH secretion; the TRH mechanism applied to the hypothyroidism, which has resolved.
Option E: Option E is incorrect because risperidone does not directly activate prolactin receptors as a partial agonist; it raises prolactin by removing dopaminergic inhibition through D2 receptor blockade.
28. [CASE 7 — QUESTION 28]
Continuing with the same patient. Her psychiatrist wishes to maintain effective psychiatric treatment while resolving the drug-induced hyperprolactinemia. Which of the following pharmacologic strategies is most mechanistically sound, and why?
A) Add metoclopramide to compete with risperidone at the lactotroph and normalize prolactin
B) Increase the risperidone dose so that greater D2 blockade eventually downregulates prolactin secretion
C) Add high-dose bromocriptine while continuing full-dose risperidone indefinitely, expecting the dopamine agonist to fully override pituitary D2 blockade without affecting psychiatric stability
D) Switch to (or augment with) aripiprazole, a partial D2 receptor agonist that provides sufficient dopaminergic tone at the pituitary lactotroph to suppress prolactin while retaining functional antagonism in mesolimbic pathways for psychiatric efficacy; aripiprazole can normalize prolactin even when added to a prolactin-elevating antipsychotic
E) Discontinue all psychiatric medication permanently, since hyperprolactinemia indicates the patient cannot tolerate any dopaminergic-active drug
ANSWER: D
Rationale:
This question asked you to select the most mechanistically sound strategy for risperidone-induced hyperprolactinemia while maintaining psychiatric treatment. Aripiprazole is a partial D2 receptor agonist: at the pituitary lactotroph, where dopamine tone is physiologically present, its partial agonism provides enough D2 receptor activation to suppress prolactin, while in mesolimbic pathways its partial agonism functions as functional antagonism sufficient for psychiatric efficacy. Switching to aripiprazole — or adding low-dose aripiprazole to the regimen — can normalize prolactin even in patients on a prolactin-elevating antipsychotic, making it the preferred mechanistic solution.
Option A: Option A is incorrect because metoclopramide is itself a D2 receptor antagonist that elevates prolactin; adding it would worsen the hyperprolactinemia.
Option B: Option B is incorrect because increasing the risperidone dose increases D2 blockade and raises prolactin further; D2 antagonism does not downregulate prolactin secretion over time.
Option C: Option C is incorrect because adding a dopamine agonist to a full-dose D2 antagonist is mechanistically self-defeating and risks destabilizing the psychiatric illness by opposing the intended mesolimbic dopamine blockade; it is not the preferred strategy.
Option E: Option E is incorrect because hyperprolactinemia does not require permanent discontinuation of all psychiatric medication; it is managed by switching to a prolactin-sparing agent such as aripiprazole, preserving needed treatment.
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.